Trial Profile

An observational clinical discovery study of Nabiximols in patients with Spinal cord injury spasticity

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nabiximols (Primary)
Indications Muscle spasticity
Focus Adverse reactions
Sponsors GW Pharmaceuticals

Most Recent Events

16 Feb 2021 According to a GW Pharmaceuticals media release, this trial is underway.
03 Nov 2020 According to a GW Pharmaceuticals media release, this study expected to start in Q1 2021.
30 Jun 2020 According to a GW Pharmaceuticals media release, the company will host a webcast today to provide insight into the U.S. Phase 3 clinical program and commercial opportunity for nabiximols.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com